论文部分内容阅读
目的探讨促性腺激素释放激素激动剂(GnRH-a)联合妈富隆治疗重度子宫内膜异位症的临床疗效,为子宫内膜异位症的治疗提供理论依据。方法选取2013年1月~2014年1月该院收治的重度子宫内膜异位症患者110例,随机分为研究组和对照组,每组各55例,所有患者均给予腹腔镜手术治疗,术后对照组给予GnRH-a治疗,研究组给予GnRH-a联合妈富隆治疗。随访1年,比较两组术前和随访1年后卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇(E2)水平,并观察围绝经期症状的严重程度评分(Kupperman)和围绝经期症状主观感受评分。结果随访1年后,两组FSH、LH以及E2水平均显著降低,与术前比较差异有统计学意义(P<0.05),但两组间比较差异无统计学意义(P>0.05);研究组Kupperman总评分和围绝经期症状主观感受总评分均显著低于对照组,两组比较差异有统计学意义(P<0.05)。结论 GnRH-a联合妈富隆治疗重度子宫内膜异位症具有较好的临床疗效,能显著改善患者的Kupperman总评分和围绝经期症状主观感受总评分。
Objective To investigate the clinical efficacy of gonadotropin-releasing hormone agonist (GnRH-a) combined with Marvelon in the treatment of severe endometriosis, and to provide a theoretical basis for the treatment of endometriosis. Methods One hundred and ten cases of severe endometriosis admitted to our hospital from January 2013 to January 2014 were randomly divided into study group and control group, with 55 cases in each group. All cases were given laparoscopic surgery, Postoperative control group was given GnRH-a treatment, the study group was given GnRH-a combined with Marvelon treatment. The patients were followed up for 1 year. The levels of follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) were compared between the two groups before and one year after follow-up. Kupperman scores and Perimenopausal symptoms subjective feelings score. Results One year after follow-up, the levels of FSH, LH and E2 were significantly decreased in both groups (P <0.05), but there was no significant difference between the two groups (P> 0.05) The total scores of Kupperman score and perimenopausal subjective feelings were significantly lower than the control group, the difference between the two groups was statistically significant (P <0.05). Conclusion GnRH-a combined with Marvelon treatment of severe endometriosis has a good clinical efficacy, can significantly improve the patient’s Kupperman total score and perimenopausal symptoms subjective total score.